Novel inhibitors of signal transducer and activator of transcription 3 signaling pathway: an update on the recent patent literature

Bibliography

• Bromberg J. STAT proteins and oncogenesis. J Clin Invest 2002;109:1139-42
   PubMed Web of Science ®Google Scholar
• Siddiquee KA, Turkson J. STAT3 as a target for inducing apoptosis in solid and hematological tumors. Cell Res 2008;18:254-67
   PubMed Web of Science ®Google Scholar
• Bowman T, Garcia R, Turkson J, et al. STATs in oncogenesis. Oncogene 2000;19:2474-88
   PubMed Web of Science ®Google Scholar
• Yu H, Jove R. The STATs of cancer- new molecular targets come of age. Nat Rev Cancer 2004;4:97-105
   PubMed Web of Science ®Google Scholar
• Turkson J, Jove R. STAT proteins: novel molecular targets for cancer drug discovery. Oncogene 2000;19:6613-26
   PubMed Web of Science ®Google Scholar
• Lavecchia A, Di Giovanni C, Novellino E. STAT-3 inhibitors: state of the art and new horizons for cancer treatment. Curr Med Chem 2011;18:2359-75
   PubMed Web of Science ®Google Scholar
• Kortylewski M, Kujawski M, Wang T, et al. Inhibiting STAT3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med 2005;11:1314-21
   PubMed Web of Science ®Google Scholar
• Wang T, Niu G, Kortylewski M, et al. Regulation of the innate and adaptive immune esponses by STAT-3 signaling in tumor cells. Nat Med 2004;10:48-54
   PubMed Web of Science ®Google Scholar
• Becker S, Groner B, Müller CW. Three-dimensional structure of the STAT3beta homodimer bound to DNA. Nature 1998;394:145-51
   PubMed Web of Science ®Google Scholar
• Ren Z, Mao X, Mertens C, et al. Crystal structure of unphosphorylated STAT3 core fragment. Biochem Biophys Res Commun 2008;374:1-5
   Google Scholar
• Reich NC, Liu L. Tracking STAT nuclear traffic. Nat Rev Immunol 2006;6:602-12
   PubMed Web of Science ®Google Scholar
• Wakahara R, Kunimoto H, Tanino K. Phospho-Ser727 of STAT3 regulates STAT3 activity byenhancing dephosphorylation of phospho-Tyr705 largely through TC45. Genes Cells 2012;17:132-45
   PubMed Web of Science ®Google Scholar
• Liddle FJ, Alvarez JA, Poli V, et al. Tyrosine phosphorylation is required for functional activation of disulfide-containing constitutively active STAT mutants. Biochemistry 2006;45:5599-605
   PubMed Web of Science ®Google Scholar
• Darnell JE Jr. STATs and gene regulation. Science 1997;277:1630-5
   PubMed Web of Science ®Google Scholar
• Yokogami K, Wakisaka S, Avruch J, et al. Serine phosphorylation and maximal activation of STAT3 during CNTF signaling is mediated by the rapamycin target mTOR. Curr Biol 2000;10:47-50
   PubMed Web of Science ®Google Scholar
• Yuan ZL, Guan YJ, Chatterjee D, et al. STAT3 dimerization regulated by reversible acetylation of a single lysine residue. Science 2005;307:269-73
   PubMed Web of Science ®Google Scholar
• Herrmann A, Vogt M, Monnigmann M, et al. Nucleocytoplasmic shuttling of persistently activated STAT3. J Cell Sci 2007;120:3249-61
   PubMed Web of Science ®Google Scholar
• Reich NC, Liu L. Tracking STAT nuclear traffic. Nat Rev Immunol 2006;6:602-12
   PubMed Web of Science ®Google Scholar
• Liu L, McBride KM, Reich NC. STAT3 nuclear import is independent of tyrosine phosphorylation and mediated by importin-alpha3. Proc Natl Acad Sci USA 2005;102:8150-5
   PubMed Web of Science ®Google Scholar
• Ma J, Cao X. Regulation of STAT3 nuclear import by importin alpha5 and importin alpha7 via two different functional sequence elements. Cell Signal 2006;18:1117-26
   PubMed Web of Science ®Google Scholar
• Page BD, Ball DP, Gunning PT. Signal transducer and activator of transcription 3 inhibitors: a patent review. Expert Opin Ther Patents 2011;21:65-83
   PubMed Web of Science ®Google Scholar
• Turkson J, Ryan D, Kim JS, et al. Phosphotyrosyl peptides block STAT3-mediated DNA binding activity, gene regulation, and cell transformation. J Biol Chem 2001;276:45443-55
   PubMed Web of Science ®Google Scholar
• Miklossy G, Hilliard TS, Turkson J. Therapeutic modulators of STAT signalling for human diseases. Nat Rev Drug Discov 2013;12:611-29
   PubMed Web of Science ®Google Scholar
• Fletcher S, Drewry JA, Shahani VM, et al. Molecular disruption of oncogenic signal transducer and activator of transcription 3 (STAT3) protein. Biochem Cell Biol 2009;87:825-33
   PubMed Web of Science ®Google Scholar
• Song H, Wang R, Wang S, et al. A low-molecular-weight compound discovered through virtual database screening inhibits STAT3 function in breast cancer cells. Proc Natl Acad Sci USA 2005;102:4700-5
   PubMed Web of Science ®Google Scholar
• Chen CL, Loy A, Cen L, et al. Signal transducer and activator of transcription 3 is involved in cell growth and survival of human rhabdomyosarcoma and osteosarcoma cells. Mol Cancer 2007;7:111
   Google Scholar
• Farjo RA. STAT3 inhibiting compositions and methods. WO042677; 2009
   Google Scholar
• Charlesson Llc. STAT3 inhibiting compositions and methods. US0077306; 2011
   Google Scholar
• Suganami E, Takagi H, Ohashi H. Leptin stimulates ischemia-induced retinal neovascularization: possible role of vascular endothelial growth factor expressed in retinal endothelial cells. Diabetes 2004;53:2443-8
   PubMed Web of Science ®Google Scholar
• Toronto Mississauga Univ, Central Florida Res Found Univ. Compounds that suppress cancer cells and exhibit antitumor activity. US0130079; 2012
   Google Scholar
• Siddiquee K, Zhang S, Guida WC, et al. Selective chemical probe inhibitor of STAT3, identified through structure-based virtual screening, induces antitumor activity. Proc Natl Acad Sci USA 2007;104:7391-6
   PubMed Web of Science ®Google Scholar
• Fletcher S, Singh J, Zhang X, et al. Disruption of transcriptionally active STAT3 dimers with non-phosphorylated, salicylic acid-based small molecules: potent in vitro and tumor cell activities. ChemBioChem 2009;10:1959-64
   Google Scholar
• Central Florida Res Found Univ, Toronto Mississauga Univ. Substituted 2-(9h-purin-9-yl) acetic acid analogues as inhibitors of STAT3. WO163424; 2011
   Google Scholar
• Central Florida Res Found Univ, Toronto Mississauga Univ. Substituted 2-hydroxy-4-(2-(phenylsulfonamido)acetamido)benzoic acid analogs as inhibitors of STAT proteins. WO018868; 2012
   Google Scholar
• Gen, Inc. Ass Pharma Valley Project Supporting Organisation, Kabushiki Kaisha Yakult, Kumamoto Health Science Univ., et al. 1,3,4-oxadiazole-2-carboxamide compound. EP2520575; 2012
   Google Scholar
• Pharma Ip General, Inc. Ass, Pharma Design, Inc., Shizuoka Prefecture, et al. 1,3,4-oxadiazole-2-carboxamide compound. WO081205; 2011
   Google Scholar
• Gen, Inc. Ass Pharma Valley Project Supporting Organisation, Pharma Design, Inc., Kabushiki Kaisha Yakult Honsha, et al. 1,3,4-oxadiazole-2-carboxamide compound. US0302524; 2012
   Google Scholar
• Pharma Ip General, Inc. Ass, Pharma Design, Inc., Shizouka Prefecture, et al. STAT3 inhibitor containing quinolinecarboxamide derivative as active ingredient. US0172429; 2011
   Google Scholar
• Piramal Life Sciences Ltd. Imidazopyridine derivatives. WO055320; 2011
   Google Scholar
• Lin L, Hutzen B, Li PK, et al. A novel small molecule, LLL12, inhibits STAT3 phosphorylation and activities and exhibits potent growth-suppressive activity in human cancer cells. Neoplasia 2010;12:39-50
   PubMed Web of Science ®Google Scholar
• Ohio State Univ. Transcription factor inhibitors and related compositions, formulations and methods. WO066263; 2011
   Google Scholar
• Ohio State Univ. Transcription factor inhibitors and related compositions, formulations and methods. US0212911; 2011
   Google Scholar
• Ohio State Univ. Transcription factor inhibitors and related compositions, formulations and methods. EP2504000A1; 2012
   Google Scholar
• Nationwide Children's Hospital, Inc., Ohio State Univ. Materials and methods to inhibit multiple myeloma cancer cells. WO097351; 2012
   Google Scholar
• Texas System Univ. Interferon therapies in combination with blockade of STAT3 activation. WO069141; 2011
   Google Scholar
• Texas System Univ. Interferon therapies in combination with blockade of STAT3 activation. US129675; 2013
   Google Scholar
• Texas System Univ. Compounds for treatment of cell proliferative diseases. WO058829; 2005
   Google Scholar
• Texas System Univ. Orally bioavailable caffeic acid related anticancer drugs. WO115269; 2007
   Google Scholar
• Texas System Univ. Orally bioavailable caffeic acid related anticancer drugs. US232668; 2007
   Google Scholar
• Heimberger AB, Priebe W. Small molecular inhibitors of p-STAT3: novel agents for treatment of primary and metastatic CNS cancers. Recent Patents CNS Drug Discov 2008;3:179-88
   Google Scholar
• Morford LA, Elliott LH, Carlson SL, et al. T cell receptor-mediated signaling is defective in T cells obtained from patients with primary intracranial tumors. J Immunol 1997;159:4415-25
   PubMed Web of Science ®Google Scholar
• Kong LY, Abou-Ghazal MK, Wei J, et al. A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells. Clin Cancer Res 2008;14:5759-68
   PubMed Web of Science ®Google Scholar
• Ferrajoli A, Faderl S, Van Q, et al. WP1066 disrupts Janus kinase-2 and induces caspase-dependent apoptosis in acute myelogenous leukemia cells. Cancer Res 2007;67:11291-9
   PubMed Web of Science ®Google Scholar
• Horiguchi A, Asano T, Kuroda K, et al. WP1066, STAT3 inhibitor WP1066 as a novel therapeutic agent for renal cell carcinoma. Br J Cancer 2010;102:1592-9
   PubMed Web of Science ®Google Scholar
• Iwamaru A, Szymanski S, Iwado E, et al. A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo. Oncogene 2007;26:2435-44
   PubMed Web of Science ®Google Scholar
• South Florida Univ. Luteolin and diosmin/diosmetin as novel STAT3 inhibitors for treating autism. US201565; 2011
   Google Scholar
• Parker-Athill E, Luo D, Bailey A, et al. Flavonoids, a prenatal prophylaxis via targeting JAK2/STAT3 signaling to oppose IL-6/MIA associated autism. J Neuroimmunol 2009;217:20-7
   PubMed Web of Science ®Google Scholar
• Weidler M, Rether J, Anke T, et al. Inhibition of interleukin-6 signaling by galiellalactone. FEBS Lett 2000;484:1-6
   PubMed Web of Science ®Google Scholar
• Partners För Utvecklingsinvesteringar Inom Life Sciences PULS Ab. Tricyclic lactones for treatment of cancer. WO010555; 2012
   Google Scholar
• Ohio State Univ, Nationwide Children S Hospital, Inc., Miami Univ. XZH-5 inhibits constitutive and interleukin-6-induced STAT3 phosphorylation in human hepatocellular carcinoma cells. WO078982; 2012
   Google Scholar
• Liu A, Liu Y, Jin Z, et al. XZH-5 inhibits STAT3 phosphorylation and enhances the cytotoxicity of chemotherapeutic drugs in human breast and pancreatic cancer cells. PLoS One 2012;7:e46624
   Google Scholar
• Liu Y, Liu A, Xu Z, et al. XZH-5 inhibits STAT3 phosphorylation and causes apoptosis in human hepatocellular carcinoma cells. Apoptosis 2011;16:502-10
   Google Scholar
• Otsuka Pharma Co. Ltd. STAT3/5 activation inhibitor. US322807; 2012
   Google Scholar
• Sen M, Tosca PJ, Zwayer C, et al. Lack of toxicity of a STAT3 decoy oligonucleotide. Cancer Chemother Pharmacol 2009;63:983-95
   Google Scholar
• Leong PL, Andrews GA, Johnson DE, et al. Targeted inhibition of STAT3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proc Natl Acad Sci USA 2003;7:4138-43
   Web of Science ®Google Scholar
• Xi S, Gooding WE, Grandis JR. In vivo antitumor efficacy of STAT3 blockade using a transcription factor decoy approach: implications for cancer therapy. Oncogene 2005;6:970-9
   Web of Science ®Google Scholar
• Zhang X, Zhang J, Wang L, et al. Therapeutic effects of STAT3 decoy oligodeoxynucleotide on human lung cancer in xenograft mice. BMC Cancer 2007;7:149
   PubMed Web of Science ®Google Scholar
• Garcia R, Bowman TL, Niu G, et al. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 2001;20:2499-513
   PubMed Web of Science ®Google Scholar
• Chan KS, Sano S, Kiguchi K, et al. Disruption of STAT3 reveals a critical role in both the initiation and the promotion stages of epithelial carcinogenesis. J Clin Invest 2004;114:720-8
   PubMed Web of Science ®Google Scholar
• Shen J, Li R, Li G. Inhibitory effects of decoy-ODN targeting activated STAT3 on human glioma growth in vivo. In vivo 2009;23:237-43
   Google Scholar
• Sen M, Thomas SM, Kim S, et al. First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapy. Cancer Discov 2012;8:694-705
   Web of Science ®Google Scholar
• Pittsburgh Univ. Mellon C. Stabilized STAT3 decoy oligonucleotides and uses therefor. WO084694; 2011
   Google Scholar
• Pittsburgh Univ. Mellon C. Stabilized STAT3 decoy oligonucleotides and uses therefor. US288536; 2012
   Google Scholar
• Grandis JR, Johnson DE, Leong P, et al. STAT3 decoy oligonucleotides and uses therefor. WO012625; 2006
   Google Scholar
• Houssier C, Depauw-Gillet MC, Hacha R, et al. Alteration in the nucleosome and chromatin structures upon interaction with platinum coordination complexes. Biochim Biophys Acta 1983;3:317-25
   Google Scholar
• Turkson J, Zhang S, Mora LB, et al. A novel platinum compound inhibits constitutive STAT3 signaling and induces cell cycle arrest and apoptosis of malignant cells. J Biol Chem 2005;38:32979-88
   Google Scholar
• Turkson J, Zhang S, Palmer J, et al. Inhibition of constitutive signal transducer and activator of transcription 3 activation by novel platinum complexes with potent antitumor activity. Mol Cancer Ther 2004;12:1533-42
   Google Scholar
• H. Lee Moffitt Cancer Cent and Res. Inst., Central Florida Res. Found Univ. Platinum compounds that inhibit constitutive STAT3 signaling and induce cell cycle arrest and apoptosis of malignant cells. WO063504; 2013
   Google Scholar
• Texas System Univ. Auranofin and auranofin analogs useful to treat proliferative disease and disorders. WO142615; 2012
   Google Scholar
• Turkson J. STAT proteins as novel targets for cancer drug discovery. Expert Opin Ther Targets 2004;8:409-22
   PubMed Web of Science ®Google Scholar
• Yue P, Turkson J. Targeting STAT3 in cancer: how successful are we? Expert Opin Investig Drugs 2009;18:45-56
   PubMed Web of Science ®Google Scholar
• Gu FM, Li QL, Gao Q, et al. Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3. World J Gastroenterol 2011;17:3922-32
   Google Scholar
• Wu WY, Li J, Wu ZS, et al. STAT3 activation in monocytes accelerates liver cancer progression. BMC Cancer 2011;11:506
   PubMed Web of Science ®Google Scholar
• Horiguchi A, Asano T, Kuroda K, et al. STAT3 inhibitor WP1066 as a novel therapeutic agent for renal cell carcinoma. Br J Cancer 2010;102:1592-9
   PubMed Web of Science ®Google Scholar
• Kim MJ, Nam HJ, Kim HP, et al. OPB-31121, a novel small molecular inhibitor, disrupts the JAK2/STAT3 pathway and exhibits an antitumor activity in gastric cancer cells. Cancer Lett 2013;335:145-52
   PubMed Web of Science ®Google Scholar
• Hintersteiner M, Ambrus G, Bednenko J. Identification of a small molecule inhibitor of importin beta mediated nuclear import by confocal on-bead screening of tagged one-bead one-compound libraries. ACS Chem Biol 2010;5:967-79
   Google Scholar
• Liu L, McBride KM, Reich NC. STAT3 nuclear import is independent of tyrosine phosphorylation and mediated by importin-alpha3. Proc Natl Acad Sci USA 2005;102:8150-5
   PubMed Web of Science ®Google Scholar